Designing anti-inflammatory drugs from parasitic worms: A synthetic small molecule analogue of the acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis

Journal of Medicinal Chemistry

Volumn 56, Issue 24, 2013, Pages 9982-10002

  Al Riyami, Lamyaa ^a   Pineda, Miguel A ^b   Rzepecka, Justyna ^a   Huggan, Judith K ^a   Khalaf, Abedawn I ^a   Suckling, Colin J ^a   Scott, Fraser J ^a   Rodgers, David T ^b   Harnett, Margaret M ^b   Harnett, William ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (DIMETHYLAMINO) N PHENYLETHANESULFONAMIDE; 2 (DIMETHYLAMINO)ETHYLHYDROGEN 4 BROMOBENZYLPHOSPHONATE TRIFLUOROACETATE; 2 (DIMETHYLAMINO)ETHYLHYDROGEN 4 METHYLBENZYLPHOSPHONATE TRIFLUOROACETATE; 2 (DIMETHYLAMINO)ETHYLHYDROGEN 4 NITROBENZYLPHOSPHONATE TRIFLUOROACETATE; 2 [[(4 BROMOBENZYL)(HYDROXY)PHOSPHORYL]OXY] N,N, TRIMETHYLAMMONIUM IODIDE; 3 (DIMETHYLAMINO)PROPYLHYDROGEN 4 METHYLBENZYLPHOSPHONATE TRIFLUOROACETATE; ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; IMMUNOGENIC PROTEIN ES 62; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; N [2 (4 MORPHOLINYL)ETHYL](2 NAPHTHYL)METHANESULFONAMIDE; N [2 (DIMETHYLAMINO)ETHYL](PHENYL)METHANESULFONAMIDE; N [2 [(4 BROMOBENZYL)SULFONYL]ETHYL] N,N DIMETHYLAMINE; N BENZYL 2 (1 PYRROLIDINYL)ETHANESULFONAMIDE; N,N DIMETHYL 2 [(4 METHYLBENZYL)SULFONYL]ETHANAMINE; N,N,N TRIMETHYL 2 [(4 METHYLBENZYL)SULFONYL]ETHANAMINIUM; NATURAL PRODUCTS AND THEIR SYNTHETIC DERIVATIVES; PHOSPHORYLCHOLINE; PROTOZOAL PROTEIN; SULFONE; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACANTHOCHEILONEMA VITEAE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DOWN REGULATION; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PROTECTION; TH17 CELL;

EID: 84891300638     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401251p     Document Type: Article

References (72)

1. de Silva, N. R.; Brooker, S.; Hotez, P. J.; Montresor, A.; Engels, D.; Savioli, L. Soil-Transmitted Helminth Infections: Updating the Global Picture Trends Parasitol. 2003, 19, 547-551
2. Hewitson, J. P.; Grainger, J. R.; Maizels, R. M. Helminth Immunoregulation: The Role of Parasite Secreted Proteins in Modulating Host Immunity Mol. Biochem. Parasitol. 2009, 167, 1-11
3. Harnett, W.; Grainger, M.; Kapil, A.; Worms, M. J.; Parkhouse, R. M. E. Origin, Kinetics of Circulation and Fate in Vivo of the Major Excretory-Secretory Product of Acanthocheilonema Viteae Parasitol. Today 1989, 99, 229-239
4. Goodridge, H. S.; Marshall, F. A.; Else, K. J.; Houston, K. M.; Egan, C.; Al-Riyami, L.; Liew, F. Y.; Harnett, W.; Harnett, M. M. Immunomodulation via Novel Use of TLR4 by the Filarial Nematode Phosphorylcholine-Containing Secreted Product, ES-62 J. Immunol. 2005, 174, 284-293
5. Goodridge, H. S.; McGuiness, S.; Houston, K. M.; Egan, C. A.; Al-Riyami, L.; Alcocer, M. J.; Harnett, M. M.; Harnett, W. Phosphorylcholine Mimics the Effects of ES-62 on Macrophages and Dendritic Cells Parasite Immunol. 2007, 29, 127-137
6. Melendez, A. J.; Harnett, M. M.; Pushparaj, P. N.; Wong, W. S.; Tay, H. K.; McSharry, C. P.; Harnett, W. Inhibition of FcepsilonRI-Mediated Mast Cell Responses by ES-62, a Product of Parasitic Filarial Nematodes Nature Med. 2007, 13, 1375-1381
7. McInnes, I. B.; Leung, B. P.; Harnett, M.; Gracie, J. A.; Liew, F. Y.; Harnett, W. A Novel Therapeutic Approach Targeting Articular Inflammation Using the Filarial Nematode-Derived Phosphorylcholine-Containing Glycoprotein ES-62 J. Immunol. 2003, 171, 2127-2133
8. Harnett, M. M.; Kean, D. E.; Boitelle, A.; McGuiness, S.; Thalhamer, T.; Steiger, C. N.; Egan, C.; Al-Riyami, L.; Alcocer, M. J.; Houston, K. M.; Gracie, J. A.; McInnes, I. B.; Harnett, W. The Phosphorycholine Moiety of the Filarial Nematode Immunomodulator ES-62 Is Responsible for Its Anti-Inflammatory Action in Arthritis Ann. Rheum. Dis. 2008, 67, 518-523
9. Pineda, M. A.; McGrath, M. A.; Smith, P. C.; Al-Riyami, L.; Rzepecka, J.; Gracie, J. A.; Harnett, W.; Harnett, M. M. The Parasitic Helminth Product ES-62 Suppresses Pathogenesis in CIA by Targeting of the IL-17-Producing Cellular Network at Multiple Sites Arthritis Rheum. 2012, 64, 3168-3178
10. Harnett, W.; Harnett, M. M.; Leung, B. P.; Gracie, J. A.; McInnes, I. B. The Anti-Inflammatory Potential of the Filarial Nematode Secreted Product, ES-62 Curr. Top. Med. Chem. 2004, 4, 553-559
11. Harnett, W.; Harnett, M. M. Immunomodulatory Activity and Therapeutic Potential of the Filarial Nematode Secreted Product, ES-62 Adv. Exp. Med. Biol. 2009, 666, 88-94
12. Kean, D. E.; Ohtsuka, I.; Sato, K.; Hada, N.; Takeda, T.; Lochnit, G.; Geyer, R.; Harnett, M. M.; Harnett, W. Dissecting Ascaris Glycosphingolipids for Immunomodulatory Moieties-The Use of Synthetic Structural Glycosphingolipid Analogues Parasite Immunol. 2006, 28, 69-76
13. Harnett, W.; Harnett, M. M. Inhibition of Murine B Cell Proliferation and Down-Regulation of Protein Kinase C Levels by a Phosphorylcholine-Containing Filarial Excretory-Secretory Product J. Immunol. 1993, 151, 4829-4837
14. Goodridge, H. S.; Marshall, F. A.; Wilson, E. H.; Houston, K. M.; Liew, F. Y.; Harnett, M. M.; Harnett, W. In Vivo Exposure of Murine Dendritic Cell and Macrophage Bone Marrow Progenitors to the Phosphorylcholine-Containing Filarial Nematode Glycoprotein ES-62 Polarizes Their Differentiation to an Anti-Inflammatory Phenotype Immunology 2004, 113, 491-498
15. Deehan, M. R.; Goodridge, H. S.; Blair, D.; Lochnit, G.; Dennis, R. D.; Geyer, R.; Harnett, M. M.; Harnett, W. Immunomodulatory Properties of Ascaris Suum Glycosphingolipids-Phosphorylcholine and Non-Phosphorylcholine-Dependent Effects Parasite Immunol. 2002, 24, 463-469
16. Lee, J. H.; Cho, M. L.; Kim, J. I.; Moon, Y. M.; Oh, H. J.; Kim, G. T.; Ryu, S.; Baek, S. H.; Lee, S. H.; Kim, H. Y.; Kim, S. I. Interleukin 17 (IL-17) Increases the Expression of Toll-Like Receptor-2, 4, and 9 by Increasing Il-1beta and Il-6 Production in Autoimmune Arthritis J. Rheumatol. 2009, 36, 684-692
17. Ultaigh, S. N.; Saber, T. P.; McCormick, J.; Connolly, M.; Dellacasagrande, J.; Keogh, B.; McCormack, W.; Reilly, M.; O'Neill, L. A.; McGuirk, P.; Fearon, U.; Veale, D. J. Blockade of Toll-Like Receptor 2 Prevents Spontaneous Cytokine Release from Rheumatoid Arthritis ex Vivo Synovial Explant Cultures Arthritis Res. Ther. 2011, 13, R33
18. Saber, T.; Veale, D. J.; Balogh, E.; McCormick, J.; NicAnUltaigh, S.; Connolly, M.; Fearon, U. Toll-Like Receptor 2 Induced Angiogenesis and Invasion Is Mediated through the Tie2 Signalling Pathway in Rheumatoid Arthritis PLoS One 2011, 6, e23540
19. Bobacz, K.; Sunk, I. G.; Hofstaetter, J. G.; Amoyo, L.; Toma, C. D.; Akira, S.; Weichhart, T.; Saemann, M.; Smolen, J. S. Toll-Like Receptors and Chondrocytes: The Lipopolysaccharide-Induced Decrease in Cartilage Matrix Synthesis Is Dependent on the Presence of Toll-Like Receptor 4 and Antagonized by Bone Morphogenetic Protein 7 Arthritis Rheum. 2007, 56, 1880-1893
20. Goh, F. G.; Midwood, K. S. Intrinsic Danger: Activation of Toll-Like Receptors in Rheumatoid Arthritis Rheumatology (Oxford, U. K.) 2012, 51, 7-23
21. Huang, Q. Q.; Pope, R. M. The Role of Toll-Like Receptors in Rheumatoid Arthritis Curr. Rheumatol. Rep. 2009, 11, 357-364
22. Abdollahi-Roodsaz, S.; van de Loo, F. A.; van den Berg, W. B. Trapped in a Vicious Loop: Toll-Like Receptors Sustain the Spontaneous Cytokine Production by Rheumatoid Synovium Arthritis Res. Ther. 2011, 13, 105
23. Hennessy, E. J.; Parker, A. E.; O'Neill, L. A. Targeting Toll-Like Receptors: Emerging Therapeutics? Nature Rev. Drug Discovery 2010, 9, 293-307
24. Whelan, M.; Harnett, M. M.; Houston, K. M.; Patel, V.; Harnett, W.; Rigley, K. P. A Filarial Nematode-Secreted Product Signals Dendritic Cells to Acquire a Phenotype That Drives Development of Th2 Cells J. Immunol. 2000, 164, 6453-6460
25. Kapadnis, P. B.; Hall, E.; Ramstedt, M.; Galloway, W. R.; Welch, M.; Spring, D. R. Towards Quorum-Quenching Catalytic Antibodies Chem. Commun. (Cambridge, U. K.) 2009, 538-540
26. Ettari, R.; Bonaccorso, C.; Micale, N.; Heindl, C.; Schirmeister, T.; Calabro, M. L.; Grasso, S.; Zappala, M. Development of Novel Peptidomimetics Containing a Vinyl Sulfone Moiety as Proteasome Inhibitors ChemMedChem 2011, 6, 1228-1237
27. Santos, M. M.; Moreira, R. Michael Acceptors as Cysteine Protease Inhibitors Mini-Rev. Med. Chem. 2007, 7, 1040-1050
28. Guay, D.; Beaulieu, C.; Percival, M. D. Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors Curr. Top. Med. Chem. 2010, 10, 708-716
29. Fairlamb, I. J.; Dickinson, J. M.; O'Connor, R.; Cohen, L. H.; van Thiel, C. F. Synthesis and Antimicrobial Evaluation of Farnesyl Diphosphate Mimetics Bioorg. Chem. 2003, 31, 80-97
30. Perruchon, J.; Ortmann, R.; Altenkamper, M.; Silber, K.; Wiesner, J.; Jomaa, H.; Klebe, G.; Schlitzer, M. Studies Addressing the Importance of Charge in the Binding of Fosmidomycin-Like Molecules to Deoxyxylulosephosphate Reductoisomerase ChemMedChem 2008, 3, 1232-1241
31. Sennhenn, P.; Mantoulidis, A.; Treu, M.; Tontsch-Grunt, U.; Spevak, W.; McConnell, D.; Schoop, A.; Bruckner, R.; Jacobi, A.; Gurler, U.; Schnapp, G.; Klein, C.; Himmelsbach, F.; Pautsch, A.; Betzemeier, B.; Herfurth, L.; Mack, J.; Wiedenmayer, D.; Bader, G.; Reiser, U. Alpha-Carbolines as Cdk-1 Inhibitors. WO/2006/131552, 2006.
32. Bursavich, M. G.; Chen, L.; Gilbert, A. M.; Hu, Y.; Jennings, L. D.; Kincaid, S. L.; Powell, D. W.; Sum, F.-W.; Zhang, Y. Anilino-Pyrimidine Analogs. US 2010 7799915, 2010.
33. Lim, C.; Lee, M.; Park, E. J.; Cho, R.; Park, H. J.; Lee, S. J.; Cho, H.; Lee, S. K.; Kim, S. Sulfonamide Derivatives of Styrylheterocycles as a Potent Inhibitor of Cox-2-Mediated Prostaglandin E2 Production Bioorg. Med. Chem. Lett. 2010, 20, 6938-6941
34. Lee, K. L.; Foley, M. A.; Chen, L.; Behnke, M. L.; Lovering, F. E.; Kirincich, S. J.; Wang, W.; Shim, J.; Tam, S.; Shen, M. W.; Khor, S.; Xu, X.; Goodwin, D. G.; Ramarao, M. K.; Nickerson-Nutter, C.; Donahue, F.; Ku, M. S.; Clark, J. D.; McKew, J. C. Discovery of Ecopladib, an Indole Inhibitor of Cytosolic Phospholipase A2alpha J. Med. Chem. 2007, 50, 1380-1400
35. McKew, J. C.; Lee, K. L.; Shen, M. W.; Thakker, P.; Foley, M. A.; Behnke, M. L.; Hu, B.; Sum, F. W.; Tam, S.; Hu, Y.; Chen, L.; Kirincich, S. J.; Michalak, R.; Thomason, J.; Ipek, M.; Wu, K.; Wooder, L.; Ramarao, M. K.; Murphy, E. A.; Goodwin, D. G.; Albert, L.; Xu, X.; Donahue, F.; Ku, M. S.; Keith, J.; Nickerson-Nutter, C. L.; Abraham, W. M.; Williams, C.; Hegen, M.; Clark, J. D. Indole Cytosolic Phospholipase A2 Alpha Inhibitors: Discovery and in Vitro and in Vivo Characterization of 4-{3-[5-Chloro-2-(2-{[(3,4- dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1 H -indol-3-yl]propyl} benzoic Acid, Efipladib J. Med. Chem. 2008, 51, 3388-3413
36. Smits, R. A.; Adami, M.; Istyastono, E. P.; Zuiderveld, O. P.; van Dam, C. M.; de Kanter, F. J.; Jongejan, A.; Coruzzi, G.; Leurs, R.; de Esch, I. J. Synthesis and Qsar of Quinazoline Sulfonamides as Highly Potent Human Histamine H4 Receptor Inverse Agonists J. Med. Chem. 2010, 53, 2390-2400
37. Goodridge, H. S.; Harnett, W.; Liew, F. Y.; Harnett, M. M. Differential Regulation of Interleukin-12 p40 and p35 Induction Via Erk Mitogen-Activated Protein Kinase-Dependent and -Independent Mechanisms and the Implications for Bioactive IL-12 and IL-23 Responses Immunology 2003, 109, 415-425
38. Goodridge, H. S.; Wilson, E. H.; Harnett, W.; Campbell, C. C.; Harnett, M. M.; Liew, F. Y. Modulation of Macrophage Cytokine Production by ES-62, a Secreted Product of the Filarial Nematode Acanthocheilonema Viteae J. Immunol. 2001, 167, 940-945
39. Harnett, W.; Harnett, M. M.; Byron, O. Structural/Functional Aspects of ES-62-a Secreted Immunomodulatory Phosphorylcholine-Containing Filarial Nematode Glycoprotein Curr. Protein Pept. Sci. 2003, 4, 59-71
40. Goodridge, H. S.; Stepek, G.; Harnett, W.; Harnett, M. M. Signalling Mechanisms Underlying Subversion of the Immune Response by the Filarial Nematode Secreted Product ES-62 Immunology 2005, 115, 296-304
41. Li, R.; Zheng, X.; Popov, I.; Zhang, X.; Wang, H.; Suzuki, M.; Necochea-Campion, R. D.; French, P. W.; Chen, D.; Siu, L.; Koos, D.; Inman, R. D.; Min, W. P. Gene Silencing of IL-12 in Dendritic Cells Inhibits Autoimmune Arthritis J. Transl. Med. 2012, 10, 19
42. Benson, J. M.; Peritt, D.; Scallon, B. J.; Heavner, G. A.; Shealy, D. J.; Giles-Komar, J. M.; Mascelli, M. A. Discovery and Mechanism of Ustekinumab: A Human Monoclonal Antibody Targeting Interleukin-12 and Interleukin-23 for Treatment of Immune-Mediated Disorders mAbs 2011, 3, 535-545
43. Tang, C.; Chen, S.; Qian, H.; Huang, W. Interleukin-23: As a Drug Target for Autoimmune Inflammatory Diseases Immunology 2012, 135, 112-124
44. Alonzi, T.; Fattori, E.; Lazzaro, D.; Costa, P.; Probert, L.; Kollias, G.; De Benedetti, F.; Poli, V.; Ciliberto, G. Interleukin 6 Is Required for the Development of Collagen-Induced Arthritis J. Exp. Med. 1998, 187, 461-468
45. Scott, D. L. Biologics-Based Therapy for the Treatment of Rheumatoid Arthritis Clin. Pharmacol. Ther. 2012, 91, 30-43
46. Kanayama, M.; Morimoto, J.; Matsui, Y.; Ikesue, M.; Danzaki, K.; Kurotaki, D.; Ito, K.; Yoshida, T.; Uede, T. Alpha9beta1 Integrin-Mediated Signaling Serves as an Intrinsic Regulator of Pathogenic Th17 Cell Generation J. Immunol. 2011, 187, 5851-5864
47. Mu, H. H.; Hasebe, A.; Van Schelt, A.; Cole, B. C. Novel Interactions of a Microbial Superantigen with TLR2 and TLR4 Differentially Regulate IL-17 and Th17-Associated Cytokines Cell. Microbiol. 2011, 13, 374-387
48. He, Z.; Shotorbani, S. S.; Jiao, Z.; Su, Z.; Tong, J.; Liu, Y.; Shen, P.; Ma, J.; Gao, J.; Wang, T.; Xia, S.; Shao, Q.; Wang, S.; Xu, H. HMGB1 Promotes the Differentiation of Th17 Via up-Regulating TLR2 and IL-23 of CD14(+) Monocytes from Patients with Rheumatoid Arthritis Scand. J. Immunol. 2012, 76, 483-490
49. Goodridge, H. S.; Deehan, M. R.; Harnett, W.; Harnett, M. M. Subversion of Immunological Signalling by a Filarial Nematode Phosphorylcholine-Containing Secreted Product Cell. Signalling 2005, 17, 11-16
50. Papp, K. A.; Langley, R. G.; Sigurgeirsson, B.; Abe, M.; Baker, D. R.; Konno, P.; Haemmerle, S.; Thurston, H. J.; Papavassilis, C.; Richards, H. B. Efficacy and Safety of Secukinumab in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Phase II Dose-Ranging Study Br. J. Dermatol. 2013, 168, 412-421
51. Papp, K. A.; Leonardi, C.; Menter, A.; Ortonne, J. P.; Krueger, J. G.; Kricorian, G.; Aras, G.; Li, J.; Russell, C. B.; Thompson, E. H.; Baumgartner, S. Brodalumab, an Anti-Interleukin-17-Receptor Antibody for Psoriasis N. Engl. J. Med. 2012, 366, 1181-1189
52. Spuls, P. I.; Hooft, L. Brodalumab and Ixekizumab, Anti-Interleukin-17- Receptor Antibodies for Psoriasis: A Critical Appraisal Br. J. Dermatol. 2012, 167, 710-713 discussion pp 714-715.
53. Ball, D. H.; Tay, H. K.; Bell, K. S.; Coates, M. L.; Al-Riyami, L.; Rzepecka, J.; Harnett, W.; Harnett, M. M. Mast Cell Subsets and Their Functional Modulation by the Acanthocheilonmea Viteae Product, ES-62 J.Parasitol. Res. 2013, 2013, 13
54. Abdollahi-Roodsaz, S.; van de Loo, F. A.; Koenders, M. I.; Helsen, M. M.; Walgreen, B.; van den Bersselaar, L. A.; Arntz, O. J.; Takahashi, N.; Joosten, L. A.; van den Berg, W. B. Destructive Role of Myeloid Differentiation Factor 88 and Protective Role of Trif in Interleukin-17-Dependent Arthritis in Mice Arthritis Rheum. 2012, 64, 1838-1847
55. Zhu, W.; London, N. R.; Gibson, C. C.; Davis, C. T.; Tong, Z.; Sorensen, L. K.; Shi, D. S.; Guo, J.; Smith, M. C.; Grossmann, A. H.; Thomas, K. R.; Li, D. Y. Interleukin Receptor Activates a Myd88-Arno-Arf6 Cascade to Disrupt Vascular Stability Nature 2012, 492, 252-255
56. Thomas, P. G.; Carter, M. R.; Atochina, O.; Da'Dara, A. A.; Piskorska, D.; McGuire, E.; Harn, D. A. Maturation of Dendritic Cell 2 Phenotype by a Helminth Glycan Uses a Toll-Like Receptor 4-Dependent Mechanism J. Immunol. 2003, 171, 5837-5841
57. van der Kleij, D.; Latz, E.; Brouwers, J. F.; Kruize, Y. C.; Schmitz, M.; Kurt-Jones, E. A.; Espevik, T.; de Jong, E. C.; Kapsenberg, M. L.; Golenbock, D. T.; Tielens, A. G.; Yazdanbakhsh, M. A Novel Host-Parasite Lipid Cross-Talk. Schistosomal Lyso-Phosphatidylserine Activates Toll-Like Receptor 2 and Affects Immune Polarization J. Biol. Chem. 2002, 277, 48122-48129
58. Al-Riyami, L.; Harnett, W. Immunomodulatory Properties of ES-62, a Phosphorylcholine-Containing Glycoprotein Secreted by Acanthocheilonema Viteae Endocr. Metab. Immune Disord. Drug Targets 2012, 12, 45-52
59. Erb, K. J. Can Helminths or Helminth-Derived Products Be Used in Humans to Prevent or Treat Allergic Diseases? Trends Immunol. 2009, 30, 75-82
60. Houston, K. M.; Babayan, S. A.; Allen, J. E.; Harnett, W. Does Litomosoides sigmodontis Synthesize Dimethylethanolamine from Choline? Parasitology 2008, 135, 55-61
61. Frostegard, J. Low Level Natural Antibodies against Phosphorylcholine: A Novel Risk Marker and Potential Mechanism in Atherosclerosis and Cardiovascular Disease Clin. Immunol. 2010, 134, 47-54
62. Sorensen, T. J.; Nielsen, M. F. Synthesis, Uv/Vis Spectra and Electrochemical Chaarcaterisation of Arylthio and Styryl Substituted Ferrocenes Cent. Eur. J. Chem. 2011, 9, 610-618
63. Choong, C.; Foord, J. S.; Griffiths, J. P.; Parker, E. M.; Baiwen, L.; Bora, M.; Moloney, M. G. Post-Polymerisation Modification of Surface Chemical Functionality and Its Effect on Protein Binding New J. Chem. 2012, 36, 1187-1200
64. Sontag, S. K.; Sheppard, G. R.; Usselman, N. M.; Marshall, N.; Locklin, J. Surface-Confined Nickel Mediated Cross-Coupling Reactions: Characterization of Initiator Environment in Kumada Catalyst-Transfer Polycondensation Langmuir 2011, 27, 12033-12041
65. Rafikov, S. R.; Ergebekov, M. E. Synthesis of p -Methylbenzylphosphonic Acid Zh. Obshch. Khim. 1964, 34, 2230-2233
66. Okamato, Y.; Iwamoto, N.; Takamuku, S. Photochemical Carbon-Phosphorus Bond Cleavage of Nitro-Substituted Benzylphosphonic Acids J. Chem. Soc., Chem. Commun. 1986, 1516-1517
67. Dolaz, M.; Yilmaz, H. Characterisation and Applications of New Azo Compounds Containing Phosphonic Acid Asian J. Chem. 2009, 21, 59085-55094
68. Meutermans, W. D. F.; Golding, S. W.; Bourne, G. T.; Miranda, L. P.; Dooley, M. J.; Alewood, P. F.; Smythe, M. L. Synthesis of Difficult Cyclic Peptides by Inclusion of a Novel Photolabile Auxiliary in a Ring Contraction Strategy J. Am. Chem. Soc. 1999, 121, 9790-9796
69. Kotsova, A. G.; Shvetsova, L. S.; Kalganova, I. I. Alkanesulfonic Acids. XII. The Reaction of 2-Chloroethanesulfonyl Chloride with Aromatic Amines Zh. Obshch. Khim. 1954, 24, 1397-1402
70. Preparation of Organic Ammonium Compounds. (Farbwerke Hoechst AG). BE632987 1963.
71. Ono, S.; Yamafuji, T.; Chaki, H.; Todo, Y.; Maekawa, M.; Kitamura, K.; Tai, M.; Narita, H. Studies on Cognitive Enhancing Agents. I. Antiamnestic and Antihypoxic Activities of 2-Dimethylaminoethyl Ethers and Related Compounds Chem. Pharm. Bull. (Tokyo) 1995, 43, 1483-1487
72. Legheand, J.; Cuisinaud, G.; Sabbagh, M.; Pabiot, N.; Seccia, M.; Cier, A. Pharmacological Study of Various N -Amide Derivatives of N ′, N ′-Disubstituted Ethylene Diamine Ann. Pharm. Fr. 1977, 35, 45-51